Liver CPT1A gene therapy reduces diet-induced hepatic steatosis in mice and highlights potential lipid biomarkers for human NAFLD

Article

Abstract: The prevalence of nonalcoholic fatty liver disease (NAFLD) has increased drastically due to the glob

Palabras claves:

AAV, CPT1A, fatty-acid oxidation, Gene therapy, hepatic steatosis, lipid biomarker, obesity

Autores:

Alonso S., Bartrons R., Calderón-Domínguez M., Casals N., Casas J., Escolà-Gil J.C., Frühbeck G., Fucho R., Herrero L., Llorente-Cortes V., Mera P., Mir J.F., Montironi C., Rodríguez A., Salvador J., Sánchez-Infantes D., Sandra Recalde, Sebastián D., Serra D., Soler-Vázquez M.C., Valentí V., Weber M., Zorzano A.

Fuentes:

scopus